SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Concord Biotech - Quaterly Results

29 May 2025 Evaluate
The sales moved up 34.77% to Rs. 4298.84 millions for the March 2025 quarter as compared to Rs. 3189.69 millions during the year-ago period.Net Profit recorded in the quarter ended March 2025 rise to 46.00% to Rs. 1419.37  millions  compared to R. 972.14 millions in corresponding previous quarter.Operating Profit saw a handsome growth to 1998.07 millions from 1450.99 millions in the quarter ended March 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 4298.84 3189.69 34.77 12000.87 10169.39 18.01 12000.87 10169.39 18.01
Other Income 93.84 108.12 -13.21 444.47 337.80 31.58 444.47 337.80 31.58
PBIDT 1998.07 1450.99 37.70 5507.79 4653.36 18.36 5507.79 4653.36 18.36
Interest 0.96 4.63 -79.27 5.29 25.52 -79.27 5.29 25.52 -79.27
PBDT 1997.11 1446.36 38.08 5502.50 4627.84 18.90 5502.50 4627.84 18.90
Depreciation 146.17 137.18 6.55 543.74 535.92 1.46 543.74 535.92 1.46
PBT 1850.94 1309.18 41.38 4958.76 4091.92 21.18 4958.76 4091.92 21.18
TAX 431.57 337.04 28.05 1229.11 1044.62 17.66 1229.11 1044.62 17.66
Deferred Tax 13.42 37.26 -63.98 39.50 46.28 -14.65 39.50 46.28 -14.65
PAT 1419.37 972.14 46.00 3729.65 3047.30 22.39 3729.65 3047.30 22.39
Equity 104.62 104.62 0.00 104.62 104.62 0.00 104.62 104.62 0.00
PBIDTM(%) 46.48 45.49 2.17 45.89 45.76 0.30 45.89 45.76 0.30

Concord Biotech Share Price

1067.40 -13.85 (-1.28%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×